Previous 10 | Next 10 |
BofA Securities has pored through the HHS details about stimulus going to healthcare providers, and notes hospitals are likely to be the biggest beneficiaries of the new guidance - while Medicare exposure puts some names in a bad relative position. More news on: Community Health Systems, I...
Over the past weekend, the U.S. Centers for Medicare & Medicaid Services distributed $30B of the planned $100B in CARES Act grants to healthcare providers as they battle COVID-19. More news on: Encompass Health Corporation, Amedisys, Inc., LHC Group, Inc., Healthcare stocks news, Stock...
A $2 trillion emergency relief package, plus a merging of Federal Reserve and Treasury functions to allow for significant quantitative easing and repo activity , is putting a floor under stocks, potentially enabling them to climb a steepening wall of worry. On March 27, I wrote an extreme...
The government's $2 trillion emergency relief package caused shares to skyrocket this week; however, the helicopter-Ben style package may inadequately address mid-term economic instability. If so, then this week's rapid run-up could be a short-term sugar high that wears off in April once disma...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
There have been a few "generational" events that have impacted stocks since I began helping professional mutual fund and hedge fund portfolio managers in the late 1990s. Covid-19 is another one of these events. These moments are incredibly scary for investors, and more broadly, society. An...
Revolution Medicines (NASDAQ: RVMD ) initiated with Buy rating and $50 (56% upside) price target at Guggenheim. Initiated with Neutral rating and $32 price target at JPMorgan. Initiated with Outperform rating at Cowen. More news on: Revolution Medicines, Inc., Amedisys, Inc., Healthcare Re...
The threat of declining earnings because of reduced economic activity caused by the spread of the coronavirus, Covid-19, has finally overtaken the unbridled optimism that's been fueled by seasonal tailwinds , a resolution of impeachment worries, and decreasing trade tensions. As a result, o...
BATON ROUGE, La., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), one of America's leading home health, hospice and personal care companies, today announced that Paul B. Kusserow, President and Chief Executive Officer, will present at the Raymond James 41 st Annual Institu...
The following slide deck was published by Amedisys, Inc. in conjunction with their 2019 Q4 earnings Read more ...
News, Short Squeeze, Breakout and More Instantly...
BATON ROUGE, La., July 24, 2024 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three and six-month periods ended June 30, 2024. Three-Month Periods Ended June 30, 2024 and 2023 Net service revenue increased $38.2 million to...
Alkermes plc (ALKS) is expected to report $0.64 for Q2 2024 Acerinox ADR (ANIOY) is expected to report for Q2 2024 Allegion plc (ALLE) is expected to report $1.77 for Q2 2024 Deutsche Bank AG (DB) is expected to report $0.43 for Q2 2024 Pathward Financial Inc. (CASH) is expected t...
Amedisys, Inc. (NASDAQ: AMED) has caught the attention of the investment community today with its bullish price action. The company's shares have moved 3.74% on the day to $95.23. Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates thr...